Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC-GEMOX with Cadonilimab and Regorafenib in Unresectable Intrahepatic Cholangiocarcinoma
NCT06335927Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- May 2023
- Primary completion
- May 2025
- Modality
- Bispecific Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab, regorafenib in intrahepatic cholangiocarcinoma (ICC), sponsored by Fudan University. Started May 2023; status: recruiting.
02
Drugs
cadonilimabregorafenib
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT06335927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06335927.